Condition
Indolent Non-Hodgkin's Lymphomas
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
100.0%
2 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
100%
2 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Terminated2
Clinical Trials (2)
Showing 2 of 2 trials
NCT01732913Phase 3TerminatedPrimary
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
NCT01732926Phase 3TerminatedPrimary
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Showing all 2 trials